News & Updates

Localized administration of colistin reduces the incidence of systemic adverse events in patients with lower respiratory tract infection (LRTI), a recent study has shown.

Real-world interim findings from the phase IV, noninterventional EMPOWER trial showed reduced attack rates and improved quality of life (QoL) in individuals who received lanadelumab for the treatment of hereditary angioedema (HAE).

Adding darolutamide to androgen-deprivation therapy (ADT) plus docetaxel significantly increases overall survival (OS) in patients with metastatic, hormone-sensitive prostate cancer (mHSPC), according to the ARASENS* trial presented at the ASCO GUCS 2022.

Upfront treatment with nivolumab plus chemotherapy continues to yield significant survival benefit compared with chemotherapy alone in patients with advanced GC/GEJC/EAC* after 24 months, regardless of their PD-L1 combined positive score (CPS), according to long-term data from the CheckMate-649 trial presented at GICS 2022.

Having a clinical pharmacist dedicated to the postsurgical patient population improves use of antimicrobial and anticoagulant agents, enhances outcomes through medication education, and boosts provider satisfactions, a study has shown.